Provided by Tiger Fintech (Singapore) Pte. Ltd.

Incyte

84.73
-0.3150-0.37%
Volume:823.50K
Turnover:70.22M
Market Cap:16.54B
PE:19.40
High:85.87
Open:85.00
Low:84.52
Close:85.04
52wk High:87.24
52wk Low:53.56
Shares:195.28M
Float Shares:163.04M
Volume Ratio:0.58
T/O Rate:0.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):4.37
EPS(LYR):0.1575
ROE:24.30%
ROA:11.52%
PB:3.97
PE(LYR):538.02

Loading ...

Syndax Pharmaceuticals Reports Q2 2025 Net Loss of $71.8M, EPS of $0.83; Revuforj Sales Surge 43% Over Q1 2025

Reuters
·
Aug 05

Incyte’s Promising Study Completion: Tafasitamab and Parsaclisib in B-cell Malignancies

TIPRANKS
·
Aug 05

Incyte’s Phase 1 Study on INCB054707: A Potential Game-Changer for Hepatic Impairment

TIPRANKS
·
Aug 05

Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Incyte (INCY)

TIPRANKS
·
Aug 04

Incyte : Mizuho Raises Target Price to $74 From $70

THOMSON REUTERS
·
Aug 04

Incyte’s Phase 3 Study on Axatilimab: A Potential Game-Changer for cGVHD Treatment

TIPRANKS
·
Aug 02

Incyte Corporation :  Barclays Initiates Coverage With Overweight Rating and Target Price $90

THOMSON REUTERS
·
Aug 01

Incyte initiated with an Overweight at Barclays

TIPRANKS
·
Aug 01

Analysts’ Top Healthcare Picks: Incyte (INCY), CVS Health (CVS)

TIPRANKS
·
Aug 01

Incyte Corp. Stock Underperforms Thursday When Compared To Competitors

Dow Jones
·
Aug 01

Knight Therapeutics Announces Regulatory Supplemental Submission of Minjuvi® (Tafasitamab) for Follicular Lymphoma in Brazil

THOMSON REUTERS
·
Aug 01

Incyte (INCY) Gets a Buy from Stifel Nicolaus

TIPRANKS
·
Jul 31

Incyte Is Maintained at Buy by Citigroup

Dow Jones
·
Jul 31

Incyte (INCY) Gets a Hold from RBC Capital

TIPRANKS
·
Jul 30

Cautious Outlook on Incyte: Sell Rating Amid Long-Term Growth Concerns and Competitive Pressures

TIPRANKS
·
Jul 30

Incyte Corporation : Deutsche Bank Raises Target Price to $65 From $60

THOMSON REUTERS
·
Jul 30

Incyte Corporation : Wells Fargo Raises Target Price to $67 From $59

THOMSON REUTERS
·
Jul 30

U.S. RESEARCH ROUNDUP-Penumbra, UnitedHealth, Visa

Reuters
·
Jul 30

Incyte : Truist Securities Raises Target Price to $79 From $73

THOMSON REUTERS
·
Jul 30

Incyte : Leerink Partners Raises Target Price to $103 From $96

THOMSON REUTERS
·
Jul 30